Dana R. Llamas

Dana Llamas practices at Riverside Medical Clinic Surgery Center in Riverside, California.

Dana Llamas' NPI, 1467817783, was assigned on December 31, 2015.

Dana Llamas' primary practice is Riverside Medical Clinic Surgery Center, at 7160 Brockton Avenue--1st Floor, Riverside, CA 92506. The practice phone is (951) 782-3801.

Dana Llamas' primary practice is Riverside Medical Clinic Surgery Center in Riverside, California. The medical group on file is Riverside Medical Clinic. Dmand AI also links Dana Llamas to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dana Llamas practices, 3 sites in all. Vendor and product names are available with a free account.

Physician assistant is Dana Llamas' primary specialty in the NPI Registry, under taxonomy code 363A00000X.

Dmand AI lists acne, benign or precancerous skin growths, cold sores or genital herpes, contact dermatitis, itchy rashes, psoriasis, rash and scalp rash among the conditions Dana Llamas treats.

CMS data shows 799 Medicare services from Dana Llamas across 8 procedure codes in 2024, for 242 Medicare patients. Medicare paid $29,354 for them. Every service was in an office.

CMS counts 242 Medicare patients who saw Dana Llamas in 2024. The largest group is 65 to 74, with 141 patients. 70% of them have high blood pressure, and 68% have high cholesterol. 8% are also on Medicaid. Their average risk score is 1.01, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dana Llamas' median patient age at 64, with 62% women.

In 2024, Dana Llamas wrote 999 Medicare Part D claims for 363 patients. 87% of them were for generic drugs. CMS names the drug for 877 of them, across 24 drugs with 11 or more claims each, at $495,909 in total drug cost.

Dana Llamas accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 215 general payments to Dana Llamas from 19 drug and device companies from 2024 to 2025. Food and beverage make up the largest share, 96% of the total. Abbvie Inc. paid the most, $743.